Navigation Links
New Study of Concerta(R) Showed Significant Improvement of ADHD Symptom Management in Adults Compared to Placebo
Date:10/26/2007

eeting pre-defined Responder criteria (p=0.009).

In the study, 229 patients with ADHD aged 18-65 years were randomized to receive CONCERTA(R) 36-108 mg/day or placebo, for seven weeks. The final analysis set contained data from 226 patients(a). Patients in the CONCERTA(R) group received a starting dose of 36 mg/day and the dose was increased in 18 mg increments every seven days (+/-2 days) for up to five weeks until response (AISRS scores decreased by 30% and CGI-I rating of 1 "very much" or 2 "much" improved) was achieved or titration to the maximum dose of 108 mg. The dose could be reduced one time during the study for tolerability reasons. The mean final dose was 67.7 mg/day.

Adverse events were reported by 93 (84.5%) of patients in the CONCERTA(R) group compared with 74 (63.8%) in the placebo group. The most commonly reported adverse events with CONCERTA(R) included decreased appetite (25.5%), headache (25.5%), dry mouth (20%), anxiety (16.4%), nausea (12.7%), increased blood pressure (10%), insomnia (9.1%), initial insomnia (7.3%), increased heart rate (7.3%), bruxism (6.4%), irritability (6.4%) and muscle tightness (6.4%). There were no serious treatment emergent adverse events reported and 16 (14.5%) and 6 (5.2%) subjects in the CONCERTA(R) and placebo groups, respectively, discontinued due to adverse events.

Today's data presentation included interim results from a long-term, open-label safety study. A similar dose titration protocol was used as in the double-blind study during the first weeks of the study after which the dose was flexible within the range of 36 to 108 mg. Interim results show that CONCERTA(R) was well tolerated in an adult population with ADHD in a dose range from 36mg to 108 mg per day for up to six months.

About ADHD

Attention Deficit Hyperactivity Disorder (ADHD) is a common and treatable neuropsychiatric condition, which includes inattention, hyperactivity and impulsivity. According to the National Institut
'/>"/>

SOURCE McNeil Pediatrics
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation ... global medical technology company, today scheduled a conference call ... of fiscal year 2013, ended April 30, 2013. The ... May 30, 2013. The Company will report financial results ... the markets close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... KNOXVILLE, Tenn. , May 23, 2013 /PRNewswire/ ... of 24-hour nurse triage and nurse advice lines, ... 10-person committee, comprising physician, nursing and administrative leaders, ... providing safe, quality and cost-effective services for hospital ... "As our national healthcare system evolves, it,s imperative ...
(Date:5/23/2013)... IRVINE, Calif. , May 23, 2013 ... breast cancer may not benefit from chemotherapy and still ... announced the launch of one of the largest sources ... The new website and interactive Facebook page provide recently ... if they can safely avoid chemotherapy. "We ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3
... Sept. 7 Epeius Biotechnologies Corporation, a leader in ... publication of a landmark paper in clinical oncology. Following ... of Rexin-G in chemo-resistant metastatic pancreatic cancer ( Molecular ... Drug and FDA Fast Track Status, this new paper ...
... India, Sept. 7 Sun Pharmaceutical Industries Ltd. (Sun) ... today announced that the Supreme Court of Israel has ... (Taro) (Pink Sheets: TAROF ) of the ... the Israeli special tender offer (STO) rules do not ...
Cached Medicine Technology:To Reach, Perchance to Kill the Cancer: A Soliloquy From Epeius Nanotechnologies Opposes That 'Sea of Troubles' 2Supreme Court of Israel Rules in Favor of Sun Pharma 2Supreme Court of Israel Rules in Favor of Sun Pharma 3
(Date:5/25/2013)... Studies from Johns Hopkins University reveal ... weight and their inability to get adequate sleep. These ... can naturally relieve many symptoms. , Johns Hopkins ... quality was significantly associated with overall weight loss, especially ... dated November 6th, 2012, researchers monitored 77 participants who ...
(Date:5/25/2013)... York (PRWEB) May 25, 2013 Pradaxa ... suffered serious, life-threatening episodes of internal bleeding while using the ... in U.S. District Court, Southern District of Illinois, Bernstein Liebhard ... website, 818 Pradaxa side effect claims had been ... That’s up from 705 claims reported by the Court on ...
(Date:5/25/2013)... According to a new market report,"Global Homeland ... MarketsandMarkets is expected to reach $544.02 Billion by ... and studies the major market drivers, restraints, and ... of the World. , Browse:, , ... 87 Figures , 175 Pages and ...
(Date:5/25/2013)... Acuity Games ’ innovative brain games have come ... Hunt is available today, expanding it beyond its iPad ... Sudoku and Matchematics will roll out over the next 30 ... brain fitness measurement have been re-optimized for the iPhone's 3.5 ... fitness measurement in your pocket. What could be better?” ...
(Date:5/25/2013)... 2013 For college students, few ... Increasingly, they are turning to prescription stimulants like ... For more on this, go to http://www.sciencedaily.com/releases/2013/05/130501145151.htm ... warns that students who pick up Adderall, “just ... for developing a physical and psychological dependency. While ...
Breaking Medicine News(10 mins):Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 2Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 3Health News:Homeland Security Market to Reach $544.02 Billion by 2018 at a CARC of 5.54% - New Report by MarketsandMarkets 4Health News:Acuity Games Apps Come to the iPhone 2Health News:Addiction and Drug Abuse: Study Drug Adderall Abuse Spikes During Finals 2
... Steven Reinberg HealthDay Reporter , THURSDAY, March 10 (HealthDay ... -- or even five cups -- daily may be reducing their ... research shows. And women who don,t drink coffee at all ... researchers noted. However, the researchers added, these findings are preliminary ...
... will find Major League pitchers practicing their pitches, perfecting ... grueling 162 game season. A new study published in ... for Psychological Science, suggests that hurlers might also consider ... brains. The study, led by researchers from Duke ...
... Man,s best friend may provide more than just faithful companionship: ... shows people who owned and walked their dogs were 34 ... The results, said epidemiologist Mathew Reeves, show that promoting ... of which fewer than half meet recommended levels of leisure-time ...
... HealthDay Reporter , THURSDAY, March 10 (HealthDay News) -- ... advantage these days often turn to what,s been nicknamed ... young minds. But researchers and pediatricians have begun ... these videos. And new studies are finding that the ...
... March 10, 2011 In an effort to improve ... cancer, the TGen Foundation today joined with key donors ... The backbone of globalCure is an alliance between ... includes leading pancreatic cancer scientists, physicians and researchers, armed ...
... -- You may have a higher long-term risk of disease ... in rats suggests. U.K. researchers found that rats were ... were malnourished while they were pregnant. The study was published ... Academy of Sciences . , , In the study, a ...
Cached Medicine News:Health News:Can Coffee Cut a Woman's Stroke Risk? 2Health News:Can Coffee Cut a Woman's Stroke Risk? 3Health News:Pitchers bean more batters in the heat of the summer 2Health News:Grab the leash: Dog walkers more likely to reach exercise benchmarks 2Health News:Popular Baby Media May Not Actually Advance Learning 2Health News:Popular Baby Media May Not Actually Advance Learning 3Health News:TGen Foundation launches 'globalCure,' targets pancreatic cancer 2Health News:Poor Diet in Pregnancy Tied to Disease in Offspring: Rat Study 2
... monitoring for flexible care settings., ... combine portability and measurement flexibility to ... of intermediate care environmentsat the patients ... heritage in patient monitoring, IntelliVue has ...
... hospital-grade monitoring capabilities into the growing health ... state management. The system is unique ... range of clinical applications, from continuous real-time ... periodic monitoring of patients outside the hospital, ...
Generra Focus 5 is a basic vital sign monitor. , ,Adult, pediatric, and neonatal. , ,Providing high quality, affordable products for efficiency in patient care....
... The Acuity Central Monitoring Station ... for up to 60 patients from ... interface uses simple point and click ... trackball. The clinician can initiate or ...
Medicine Products: